Imaging of tumor hypoxia to predict treatment sensitivity.

Non-invasive detection of tumor hypoxia using radiolabeled 2-nitroimidazoles has been a major effort during the last two decades. Recent years have witnessed the introduction of several new compounds which are chemically related to [(18)F]fluoromisonidazole (FMISO) but show slight but distinct differences in biodistribution and metabolic clearance. Although [(18)F]FMISO has shown clinical potential it suffers from suboptimal oxygen dependent tissue contrast and newer agents seek to improve this essential feature. The limited data on other interesting tracers keeps the investigators busy at demonstrating the potential advantages over [(18)F]FMISO while efforts should start to concentrate on proving the clinical significance of such techniques in the form of outcome data from image-guided therapy modification. We review here our experiences with two hypoxia-avid agents [(18)F]fluoroerythronitromidazole (FETNIM) and [(18)F] 2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide (EF5) and focus on the similarities and differences of these two tracers in comparison to other radiolabeled 2-nitroimidazoles. It is recognized that only [(18)F]FMISO has thus far shown clinical utility and newer tracers need to be tested against this circumstance.

Atomic absorption spectrophotometry of chromium in serum and urine with a modified Perkin-Elmer 603 atomic absorption spectrophotometer.

Modification of a Perkin-Elmer 603 atomic absorption spectrophotometer by adding a high-intensity tungsten-halogen lamp for background correction significantly improved the detection limit for elements that have analytical wavelengths in the near-ultraviolet and visible regions. Chromium in human serum and urine can be measured, with a simplified sample-handling technique, in concentrations of less than 0.1 microgram/liter. For comparison, the mean value for chromium in the serum of eight men was 0.14 microgram/liter.